Fondazione Poliambulanza

The site conducts a large share of its clinical research in oncology, with a strong focus on colorectal cancer, gastric cancer, pancreatic cancer, and ovarian cancer. These studies are designed to evaluate new treatment approaches, refine biomarker-driven care, and improve outcomes for patients with advanced or high-risk disease.

• Studies in neoplasms and advanced digestive cancers
• Research on metastatic colorectal cancer, gastric adenocarcinoma, and pancreatic ductal adenocarcinoma
• Trials testing whether newer targeted or combination therapies can improve survival and disease control
• Work on personalized treatment selection using tumor markers and circulating tumor DNA

Overall, the oncology unit at Fondazione Poliambulanza is especially active in studies that aim to make cancer treatment more precise, more effective, and better matched to each patient’s disease profile.

A major research theme is colorectal cancer, including locally advanced, metastatic, and post-surgical settings. Many trials explore how biomarkers such as RAS, BRAF, and circulating tumor DNA can help guide treatment choice and identify patients most likely to benefit from specific therapies.

• Metastatic colorectal cancer and colon cancer in first-line and later-line treatment
• Studies of ctDNA to guide adjuvant treatment decisions after surgery
• Trials comparing targeted combinations with standard chemotherapy-based approaches
• Research aimed at improving progression-free and overall survival in molecularly selected patients

This research portfolio reflects a strong interest in moving beyond one-size-fits-all care and toward more tailored strategies for colorectal cancer management.

The site also participates in trials for gastric cancer, gastroesophageal junction adenocarcinoma, and pancreatic adenocarcinoma. These studies are focused on testing new targeted and immune-based treatment combinations for patients with advanced disease.

• Gastric and gastroesophageal junction cancers with specific biomarker profiles
• Pancreatic cancer, including metastatic pancreatic adenocarcinoma
• Evaluation of combination therapies intended to improve survival and disease control
• Research that uses tumor markers to match patients with more suitable treatments

These trials show an emphasis on bringing more personalized options to difficult-to-treat digestive system cancers at Fondazione Poliambulanza.

Another important area is gastroenterology, especially Crohn’s disease, ulcerative colitis, and bile acid diarrhoea. The trials in this field aim to improve symptom control, maintain remission, and evaluate better treatment options for chronic digestive conditions.

• Moderately to severely active Crohn’s disease
• Ulcerative colitis and maintenance of remission
• Bile acid diarrhoea and treatment of persistent bowel symptoms
• Studies assessing whether new therapies can offer better long-term control and tolerability

This work supports patients living with ongoing inflammatory and functional bowel disorders by exploring treatments that may improve daily quality of life.

Beyond cancer and digestive disease, the site includes studies in cardiovascular disease and musculoskeletal disease. These trials address both acute and chronic conditions, with a focus on safer treatment strategies and better symptom relief.

• Acute myocardial infarction and antithrombotic treatment after PCI in patients with atrial fibrillation
• Research on reducing bleeding risk while preserving protection against cardiac and cerebral events
• Knee osteoarthritis studies aimed at easing pain and improving function
• Evaluation of new approaches for common non-cancer conditions seen in everyday clinical practice

These projects broaden the research profile of Fondazione Poliambulanza by addressing important conditions outside oncology that still have a major impact on patient health.

Several trials at the site focus on diagnostic techniques, precision medicine, and treatment planning based on individual disease characteristics. This includes studies that use liquid biopsy, tissue markers, and endoscopic assessment to support more informed care decisions.

• Circulating tumor DNA used to guide post-operative treatment intensity
• Biomarker-driven treatment selection in solid tumors
• Research into improving diagnostic and follow-up strategies for cancer and digestive diseases
• Studies evaluating whether personalized care can improve outcomes compared with standard approaches

This reflects a broader commitment to combining clinical treatment with better diagnostic and analytical techniques for more precise patient care.